Want to see KURA full AI Analyst Report?
KURA Stock Chart & Stats
$10.39
-$0.06(-0.57%)
At close: 4:00 PM EDT
$10.39
-$0.06(-0.57%)
Day’s Range― - ―
52-Week Range$6.95 - $12.49
Previous CloseN/A
Volume1.14M
Average Volume (3M)1.51M
Market Cap
$897.61M
Enterprise Value$480.17
Total Cash (Recent Filing)$519.02M
Total Debt (Recent Filing)$24.45M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Oct 29, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.37
Shares Outstanding88,960,620
10 Day Avg. Volume1,083,218
30 Day Avg. Volume1,513,902
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.22Price Target Upside171.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.49
Revenue Forecast (FY)$95.04M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumSustained early commercial uptake and repeat prescribing indicate product-market fit and a functioning commercial model. Durable adoption metrics (new starts, repeat scripts, physician switching) lessen go-to-market execution risk and create a foundation for scalable, recurring oncology revenues if maintained.
High Payer AccessBroad formulary coverage materially reduces reimbursement and access barriers, supporting durable uptake and steady prescribing in oncology. Favorable payer placement improves pricing predictability, shortens commercialization friction and raises likelihood that launch momentum can translate into consistent long-term sales.
Collaboration Funding Extends RunwayMaterial cash balances combined with expected milestone payments reduce near-term financing risk and permit completion of pivotal Phase 3 work. A funded path to topline readout preserves optionality, allows sustained R&D/launch investment, and de-risks the program timing vs immediate capital raises.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow forces reliance on external financing or partner payments to sustain operations. Over the medium term this increases dilution risk and constrains strategic flexibility, particularly if clinical setbacks or slower-than-expected commercial uptake lengthen the path to profitability.
Widening Net LossesExpanding quarterly losses reflect heavier investment in development and commercialization. If revenue growth does not scale as planned, continued widening losses will erode equity and raise funding needs, increasing execution risk and potentially forcing trade-offs between R&D programs and commercial expansion.
Reliance On Collaboration RevenueMaterial reliance on partner-derived collaboration revenue introduces timing and recognition variability that can distort near-term resources. Dependence on anticipated milestone payments for runway makes funding conditional on counterparties and contract timing, leaving the company exposed if payments shift or are delayed.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $6.95 and its highest was $12.49 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $897.61M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Oct 29, 2026 which is in 74 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Aug 12, 2026. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.877 by $0.107.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.83.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,960,620 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.877. Following the earnings report the stock price went up 1.509%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.22 (171.63% Upside)
$28.22 (171.63% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 203.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.87%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. (KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology therapeutics for the treatment of cancer. The company’s activities center on advancing a pipeline of small-molecule drug candidates through clinical development, with a focus on genetically defined cancers and targeted approaches intended to address specific oncogenic drivers or resistance mechanisms.
KURA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial traction for COMZIFTI (notable revenue, majority share of new patient starts, high Q/Q growth in starts and prescriptions), robust clinical data across Ziftomenib and promising darlifarnib combination signals in multiple solid tumor settings. Financials show solid funding runway with Kyowa Kirin support but also reflect increased commercial spend, a declining cash balance since year‑end, and a YoY decline in collaboration revenue. Competitive noise around market share and the multi‑year timelines to pivotal readouts add uncertainty. Overall, positive operational and clinical momentum is balanced against near‑term financial and competitive considerations.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$28.22
▲(171.63% Upside)
Technical Analysis
Geron
―
CytomX Therapeutics
―
Zentalis Pharmaceuticals
―
Oric Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
2.37% Insiders
10.76% Mutual Funds
41.08% Other Institutional Investors
28.89% Public Companies and Individual Investors